DXCM
DexCom Inc
NASDAQ: DXCM · HEALTHCARE · MEDICAL DEVICES
$59.33
+0.37% today
Updated 2026-06-05
Market cap
$29.08B
P/E ratio
32.35
P/S ratio
6.04x
EPS (TTM)
$2.33
Dividend yield
—
52W range
$54 – $90
Volume
6.1M
WallStSmart proprietary scores
72
out of 100
Grade: B
Buy
Investment rating
8.7
Growth
A7.0
Quality
B+8.5
Profitability
A6.7
Valuation
B5/9
Piotroski F-Score
Moderate
2.7
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →199 stocks currently score above 75
Price targets
Analyst target
$85.33
+43.82%
12-Month target
$63.19
+6.51%
Intrinsic (DCF)
$664.17
Margin of safety
+89.74%
3 Strong Buy21 Buy3 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ ROE 31.47% — strong efficiency
+ Free cash flow $449.00M — positive
+ Revenue growth 15.00% QoQ
+ 89.74% below intrinsic value
+ Debt/equity 0.47x — low leverage
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $2.91B | $3.62B | $4.03B | $4.66B | $4.82B | $5.3B |
| Net income | $341.20M | $541.50M | $576.20M | $836.30M | $199.50M | — |
| EPS | — | — | — | — | $2.33 | $2.54 |
| Free cash flow | $304.70M | $511.90M | $630.70M | $1.08B | $449.00M | — |
| Profit margin | 11.73% | 14.95% | 14.29% | 17.94% | 19.30% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-04 | COLEMAN, JON | Sale | 4,911 | $74.13 |
| 2026-06-03 | COLEMAN, JON | Sale | 4,912 | $73.00 |
| 2026-05-28 | OSTERLOH, ALBERT FREDERICK IV | Buy | 1,630 | — |
Peer comparison
Smart narrative
DexCom Inc trades at $59.33. representing a P/E of 32.35x trailing earnings. Our Smart Value Score of 72/100 indicates the stock is good. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 2.67, it sits in the grey zone. TTM revenue stands at $4.82B. with profit margins at 19.30%. Our DCF model estimates intrinsic value at $664.17.
Frequently asked questions
What is DexCom Inc's stock price?
DexCom Inc (DXCM) trades at $59.33, on a P/E of 32.4x and a P/S of 6.0x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is DexCom Inc overvalued?
DexCom Inc carries a Smart Value Score of 72/100 (Grade B), which we rate Buy. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $664.17 versus the $59.33 price, a 89.7% margin of safety on a cash flow basis.
What is the price target of DexCom Inc (DXCM)?
The 12-month analyst consensus target is $85.33, about 43.8% above the current $59.33. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of DXCM by 2030?
Our research-backed model puts the 2030 base case at $261.32, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of DexCom Inc (DXCM)?
Our DCF model estimates intrinsic value at $664.17, a +89.7% margin of safety versus today's $59.33. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is DexCom Inc's revenue?
DexCom Inc's trailing twelve-month revenue is $4.82B, and our model projects it reaching about $8.52B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
DexCom Inc's Altman Z-Score is 2.67, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio6.04x
ROE31.47%
Beta1.44
50D MA$65.87
200D MA$67.57
Shares out0.39B
Float0.38B
Short ratio—
Avg volume6.1M
Performance
1 week-3.24%
1 month-4.41%
3 months+3.11%
YTD+3.84%
1 year—
3 years—
5 years—